Skip to main content
. 2010 Oct-Dec;27(4):230–235. doi: 10.4103/0970-2113.71957

Table 1.

Studies showing results of utilization of inhaled corticosteroids in acute exacerbation of COPD

Authors No of pts. studied Treatment given Therapeutic outcome Side effects
Morice et al.[24] 19 Nebulized budesonide -2 mg bid Oral prednisolone -30 mg OD Clinical efficacy was similar in both the groups Urinary steroid metabolites were higher in budesonide group
Maltais et al.[25] 199 Nebulized budesomde -2 mg 6 hrly Oral prednisolone -30 mg 12 hrly Placebo FEV1 improvement was similar to oral prednisolone Borg scale rating was similar in both groups Higher incidence of hyperglycemia with oral prednisolone
Mirici et al.[26] 40 Nebulized budesomde -8 mg daily IV Preddnisolone -40 mg OD Similar clinical efficacy as parental steroids in expiratory flow rates, PaO2 PaCO2 and SaO2, values Minimal side effects
Gunen et al.[15,27] 159 Nebulized budesomde -1.5 mg 6 hrly Oral prednisolone -40 mg OD Standard bronchodilator therapy Significant improvement in FVC, FEV1 FEF25-75% and PaO2 in budesonide group Relapse and re-hospitalization rates were reduced by half in budesonide group Hyperglycemia in oral prednisolone group
Wei et al.[28] 60 Nebulized budesomde Oral prednisolone Control group Dyspnea score, FEV1 and improvement in ABG were significantly better in budesonide group Mmimal side effects
Guozhong et al.[29] 40 Nebulized budesomde Control group Better improvement in FEV1 and PaO2 values in budesonide group Nil
Marcus et al.[30] 25 Budesomde suspension -0.5 mg 12 hrly MDI/DPI Reduction in exacerbation rates Improvement in FEV1, better symptom control, increased confidence with budesonide Minimal side effects
Gaude and Nemagouda[31] 125 Nebulized budesonide -2 mg bid IV Hydrocortisone -100 mg 6 hrly Spirometry variables, SpO2 improvement similar in both groups Minimal side effects
HRQL score better improved with budesonide Duration of hospitalization shorter in budesomde group